Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Neuropsychopharmacology

• Publication date

  2008-08-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1038/sj.npp.1301624PMID 18004285
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2.5 Redox Dysregulation in Schizophrenia: Genetic Susceptibility and Pathophysiological Mechanisms

  2009cited by this paper
• Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence

  2007cited by this paper
• Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats: relevance to schizophrenia.

  2007cited by this paper
• Learning-Induced Plasticity in Auditory Spatial Representations Revealed by Electrical Neuroimaging

  2007cited by this paper
• Boundary Completion Is Automatic and Dissociable from Shape Discrimination

  2006cited by this paper
• Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: Relevance to schizophrenia.

  2006cited by this paper
• Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene.

  2006cited by this paper
• Support for an association between mismatch negativity and social functioning in schizophrenia.

  2006cited by this paper
• Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia.

  2006cited by this paper
• Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures.

  2006cited by this paper
• Carbofuran-induced neurochemical and neurobehavioral alterations in rats: attenuation by N-acetylcysteine

  2006cited by this paper
• Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis

  2006cited by this paper
• Protective effect of N-acetyl-L-cysteine on amyloid beta-peptide-induced learning and memory deficits in mice.

  2006cited by this paper
• Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia.

  2005cited by this paper
• An event-related potential study on the impairment of automatic processing of auditory input in schizophrenia

  2005influential reference
• Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia.

  2005influential reference
• Cluster Validation by Prediction Strength

  2005cited by this paper
• Altered Glutathione Redox State in Schizophrenia

  2005cited by this paper
• Mismatch negativity deficits are associated with poor functioning in schizophrenia patients.

  2005cited by this paper
• Synthesizing schizophrenia: a bottom-up, symptomatic approach.

  2005influential reference
• Early-stage visual processing deficits in schizophrenia

  2005cited by this paper
• Mapping event-related brain potential microstates to sentence endings

  2005cited by this paper
• Electrical neuroimaging based on biophysical constraints

  2004cited by this paper
• Noninvasive Localization of Electromagnetic Epileptic Activity. I. Method Descriptions and Simulations

  2004cited by this paper
• An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in osteogenic disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development.

  2004cited by this paper
• EEG source imaging.

  2004cited by this paper
• Noninvasive Localization of Electromagnetic Epileptic Activity. II. Demonstration of Sublobar Accuracy in Patients with Simultaneous Surface and Depth Recordings

  2004cited by this paper
• Pharmacokinetics of N-acetylcysteine in man

  2004cited by this paper
• Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine

  2004cited by this paper
• Rapid discrimination of visual and multisensory memories revealed by electrical neuroimaging

  2004cited by this paper
• Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia.

  2004cited by this paper
• The antioxidants α‐lipoic acid and N‐acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice

  2003cited by this paper
• N-acetylcysteine reduced the effect of ethanol on antioxidant system in rat plasma and brain tissue.

  2002cited by this paper
• Measurement of homocysteine and other aminothiols in plasma: advantages of using tris(2-carboxyethyl)phosphine as reductant compared with tri-n-butylphosphine.

  2001cited by this paper
• Redox modulation of the NMDA receptor

  2000cited by this paper
• Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

  2000cited by this paper
• Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo

  2000cited by this paper
• Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia.

  2000influential reference
• Diagnostic interview for genetic studies (DIGS): inter-rater and test-retest reliability of the French version

  1999cited by this paper
• Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia.

  1999cited by this paper
• Detection of glutathione in the human brain in vivo by means of double quantum coherence filtering

  1999cited by this paper
• Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia

  1998influential reference
• Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/interdeviant interval.

  1998influential reference
• N-acetylcysteine: pharmacological considerations and experimental and clinical applications.

  1997cited by this paper
• In vivo indices of oxidative stress in lead-exposed C57BL/6 mice are reduced by treatment with meso-2,3-dimercaptosuccinic acid or N-acetylcysteine.

  1996cited by this paper
• Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia.

  1996cited by this paper
• Brain potential evidence for an auditory sensory memory deficit in schizophrenia.

  1995influential reference
• Role of plasma homocyst(e)ine in arterial occlusive diseases.

  1994cited by this paper
• Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative.

  1994cited by this paper
• Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects.

  1994cited by this paper
• NMDA receptor channels: subunit-specific potentiation by reducing agents.

  1994cited by this paper
• Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

  1994cited by this paper
• The Diagnostic Interview for Genetic Studies

  1994cited by this paper
• Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study.

  1993influential reference
• Glutathione modulates the N-methyl-D-aspartate receptor-activated calcium influx into cultured rat cerebellar granule cells.

  1993influential reference
• Event-related potentials to repetition and change of auditory stimuli.

  1992cited by this paper
• Mismatch negativity: an index of a preattentive processing deficit in schizophrenia.

  1991influential reference
• Recent advances in the phencyclidine model of schizophrenia.

  1991cited by this paper
• Redox modulatory site of the NMDA receptor–channel complex: Regulation by oxidized glutathione

  1991influential reference
• Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man.

  1990cited by this paper
• Principles of spatial analysis

  1987cited by this paper
• Mapping of scalp potentials by surface spline interpolation.

  1987cited by this paper
• Methods of Analysis of Brain Electrical and Magnetic Signals

  1987cited by this paper
• Intracellular cysteine and glutathione delivery systems.

  1986cited by this paper
• Glutathione.

  1983cited by this paper
• Reference-free identification of components of checkerboard-evoked multichannel potential fields.

  1980cited by this paper
• Early selective-attention effect on evoked potential reinterpreted.

  1978cited by this paper
• Evoked Potential Correlates of Auditory Signal Detection

  1971cited by this paper
• Cerebral Cortex Advance Access published March 16, 2005 Filling-in in Schizophrenia: a High-density Electrical Mapping and Source-analysis Investigation of Illusory Contour Processing

  year unknowncited by this paper

• Biomarker innovations in precision psychiatry diagnostics and treatment strategies.

  2026cites this paper
• Non-canonically regulated heterochronic expression of Hsp70 drives clonal expansion and invasion in Drosophila epithelial tumours

  2026cites this paper
• Novel drug treatments for schizophrenia.

  2026cites this paper
• Schizophrenia and amino acids in diet – it is possible to enhance treatment through nutrition?

  2025cites this paper
• Evaluation of Glutathione T 2 in the Human Brain Using J‐Difference MRS at 3 T: Multicenter Multivendor Study

  2025cites this paper
• Neurophysiology of mismatch negativity generation: a biophysical modeling study

  2025cites this paper
• N-Acetylcysteine Mitigates Ketamine Neurotoxicity in Young Rats by Modulating ROS-Mediated Pyroptosis and Ferroptosis

  2025influential citation
• The neuroprotective effects of N-acetylcysteine in psychiatric and neurodegenerative disorders: From modulation of glutamatergic transmission to restoration of synaptic plasticity.

  2025cites this paper
• Neuroinflamation Treatment Options in Resistant Schizophrenia—State of the Art

  2025influential citation
• Effect of N-Acetylcysteine on mortality in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.

  2025cites this paper
• The antioxidant N-acetylcysteine prevents cortical neuropathological phenotypes caused by adolescent Δ-9-tetrahydrocannabinol exposure in male rats

  2025cites this paper
• Antipsychotics and dietary interventions: Pharmacodynamics, pharmacokinetics, and synergisms in therapy.

  2025cites this paper
• Ferroptosis in schizophrenia: Mechanisms and therapeutic potentials (Review)

  2024cites this paper
• Reactivating PTEN to impair glioma stem cells by inhibiting cytosolic iron-sulfur assembly

  2024cites this paper
• Making bloodwork work: the impact of sample collection, processing, and storage on plasma glutathione measurement, and implications for translation

  2024cites this paper
• N-Acetylcysteine and a Specialized Preventive Intervention for Individuals at High Risk for Psychosis: A Randomized Double-Blind Multicenter Trial

  2024cites this paper
• Early auditory processing dysfunction in schizophrenia: mechanisms and implications.

  2023cites this paper
• Mycobacterium smegmatis secreting methionine sulfoxide reductase A (MsrA) modulates cellular processes in mouse macrophages.

  2023cites this paper
• Connecting Neurobiological Features with Interregional Dysconnectivity in Social-Cognitive Impairments of Schizophrenia

  2023cites this paper
• Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine.

  2023cites this paper
• Cerebral venous congestion alters brain metabolite profiles, impairing cognitive function

  2023cites this paper
• Apathy and Motivation: Biological Basis and Drug Treatment.

  2023cites this paper
• Bridging the gaps towards precision psychiatry: Mechanistic biomarkers for early detection and intervention.

  2023cites this paper
• Influence of dose and exposition time in the effectiveness of N-Acetyl-l-cysteine treatment in A549 human epithelial cells

  2023cites this paper
• Why mismatch negativity continues to hold potential in probing altered brain function in schizophrenia

  2023cites this paper
• Redox and Immune Signaling in Schizophrenia: New Therapeutic Potential

  2023cites this paper
• Serum free thiols in recently diagnosed patients with schizophrenia spectrum disorder: A potentially useful biomarker of oxidative stress.

  2023cites this paper
• The protective effect of N-acetylcysteine against MK-801-induced neurodegeneration in mice

  2023cites this paper
• Schizophrenia Synaptic Pathology and Antipsychotic Treatment in the Framework of Oxidative and Mitochondrial Dysfunction: Translational Highlights for the Clinics and Treatment

  2023cites this paper
• Niosomes loading N-acetyl-L-cysteine for cancer treatment in vivo study

  2023influential citation
• Role of mitochondria in brain functions and related disorders

  2022cites this paper
• Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis

  2022cites this paper
• Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia

  2022cites this paper
• Neuroinflammation in Schizophrenia: The Key Role of the WNT/β-Catenin Pathway

  2022cites this paper
• The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders

  2022cites this paper
• The distinction between temporal order and duration processing, and implications for schizophrenia

  2022cites this paper
• Auditory event-related potentials in separating patients with depressive disorders and non-depressed controls: A narrative review.

  2022cites this paper
• Cognitive impairments in schizophrenia and their impact on oxidative stress

  2022cites this paper
• Cautionary Observations Concerning the Introduction of Psychophysiological Biomarkers into Neuropsychiatric Practice

  2022cites this paper
• Oxindole-curcumin hybrid compound enhances the transcription of γ-glutamylcysteine ligase.

  2021cites this paper
• Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives

  2021cites this paper
• Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry

  2021cites this paper
• N‐acetylcysteine as a new prominent approach for treating psychiatric disorders

  2021cites this paper
• Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions

  2021cites this paper
• Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms revealed by laboratory studies.

  2021cites this paper
• Sources of the frontocentral mismatch negativity and P3a responses in schizophrenia patients and healthy comparison subjects.

  2021cites this paper
• N-Acetylcysteine versus arsenic poisoning: A mechanistic study of complexation by molecular spectroscopy and density functional theory

  2021cites this paper
• Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia

  2021cites this paper
• Timely N-Acetyl-Cysteine and Environmental Enrichment Rescue Oxidative Stress-Induced Parvalbumin Interneuron Impairments via MMP9/RAGE Pathway: A Translational Approach for Early Intervention in Psychosis

  2021cites this paper
• Oxidative Stress in the Early Stage of Psychosis.

  2021cites this paper
• N-Acetylcysteine (NAC): Impacts on Human Health

  2021cites this paper
• Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058

  2021cites this paper
• N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks)

  2021cites this paper
• Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia

  2021cites this paper
• In Vivo Brain GSH: MRS Methods and Clinical Applications

  2021cites this paper
• Use of cognitive event-related potentials in the management of psychiatric disorders: Towards an individual follow-up and multi-component clinical approach

  2021cites this paper
• Potential Novel Therapies for Neurodevelopmental Diseases Targeting Oxidative Stress

  2021cites this paper
• Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients

  2020cites this paper
• Stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder

  2020cites this paper
• Alpha7 nicotinic‐N‐methyl‐D‐aspartate hypothesis in the treatment of schizophrenia and beyond

  2020cites this paper
• Brain foods - the role of diet in brain performance and health.

  2020cites this paper
• Destruction of ERP responses to deviance in an auditory oddball paradigm in amyloid infusion mice with memory deficits

  2020cites this paper
• Hippocampal Hyperactivity as a Druggable Circuit-Level Origin of Aberrant Salience in Schizophrenia

  2020cites this paper
• BODIPY-Hg_2+ Complex: A Fluorescence “Turn-ON” Sensor for Cysteine Detection

  2020cites this paper
• Naturalne metody wspomagania odporności w walce z koronawirusem

  2020cites this paper
• Abnormal Effective Connectivity Underlying Auditory Mismatch Negativity Impairments in Schizophrenia.

  2020cites this paper
• Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches

  2020cites this paper
• Unique contributions of sensory discrimination and gamma synchronization deficits to cognitive, clinical, and psychosocial functional impairments in schizophrenia

  2020cites this paper
• N-Acetylcysteine InhibitsKynurenine Aminotransferase II.

  2020cites this paper
• Neurophysiological Biomarkers in Schizophrenia—P50, Mismatch Negativity, and TMS-EMG and TMS-EEG

  2020cites this paper
• Progressive Impairment of Mismatch Negativity Is Reflective of Underlying Pathophysiological Changes in Patients With First-Episode Psychosis

  2020cites this paper
• Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients.

  2020cites this paper
• Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia †

  2020cites this paper
• Potential Roles of Redox Dysregulation in the Development of Schizophrenia.

  2020cites this paper
• A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology

  2020cites this paper
• Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention.

  2020cites this paper
• Hierarchical Pathways from Sensory Processing to Cognitive, Clinical, and Functional Impairments in Schizophrenia.

  2020cites this paper
• Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders

  2020cites this paper
• Reduction of oxidative stress improves insulin signaling in cardiac tissue of obese mice

  2020cites this paper
• Elucidating the glutamatergic processes underlying mismatch negativity deficits in early stage bipolar disorder and schizophrenia: A combined 1H-MRS and EEG study.

  2019cites this paper
• MEGA-PRESS and PRESS measure oxidation of glutathione in a phantom.

  2019cites this paper
• Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study.

  2019cites this paper
• ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis

  2019cites this paper
• Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia

  2019cites this paper
• Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia

  2019cites this paper
• Validation of oxidative stress assay for schizophrenia.

  2019cites this paper
• N-acetylcysteine improves EEG measures of auditory deviance detection and neural synchronization in schizophrenia: A randomized, controlled pilot study.

  2019cites this paper
• Electroencephalography and Staging

  2019cites this paper
• l-Cysteine

  2019cites this paper
• N-Acetyl-Cysteine Supplementation Improves Functional Connectivity Within the Cingulate Cortex in Early Psychosis: A Pilot Study

  2019cites this paper
• Applications of Neurophysiological Biomarkers in CNS Drug Development: Focus on Psychoses

  2019cites this paper
• Staging model in psychiatry: Review of the evolution of electroencephalography abnormalities in major psychiatric disorders

  2019cites this paper
• Multimodal prevention of first psychotic episode through N‐acetyl‐l‐cysteine and integrated preventive psychological intervention in individuals clinically at high risk for psychosis: Protocol of a randomized, placebo‐controlled, parallel‐group trial

  2019cites this paper
• Alternative Treatments for Obsessive-Compulsive Disorder: Nutraceuticals and Lifestyle Interventions

  2019cites this paper
• Efficacy of N-acetyl Cysteine in Patients with Dyspepsia with Negative Helicobacter pylori Infection

  2019cites this paper
• Recycling N-acetylcysteine: A review of evidence for adjunctive therapy in schizophrenia

  2019cites this paper
• Diverse Responses of Neurons and Monocytes to Titanium Dioxide Nanoparticle Exposure

  2019cites this paper
• NMDA Receptor Antagonist Effects on Speech-Related Mismatch Negativity and Its Underlying Oscillatory and Source Activity in Healthy Humans

  2019cites this paper
• Can N‑acetylcysteine, varenicline, or the combination prevent psychosis by enhancing mismatch negativity?

  2019cites this paper
• Glutamate modulators for treatment of schizophrenia

  2019cites this paper